Upadacitinib tartrate tetrahydrate

Upadacitinib tartrate tetrahydrate purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. [Abstract]

Customer Validation
PBLs isolated from healthy participants (n = 6) were pretreated with either vehicle control (0.01% DMSO) or JAK inhibitor Upadacitinib (1 µM, 100 nM, 10 nM) before LPS stimulation. Secreted IL-6 and IL-1β were measured by ELISA 48 hours post-stimulation.

Upadacitinib tartrate tetrahydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 29;16(1):6972. [Abstract]

Customer Validation
Cell survival of SUM149 BRCA1-Mut and BRCA1-Rev cells transfected with a concentration range (nM) of ADAR1 siRNA in the context of exposure to the JAK/STAT pathway inhibitor Upadacitinib ( 32 µM).

Upadacitinib tartrate tetrahydrate purchased from MedChemExpress. Usage Cited in: Cell. 2024 Jan 4;187(1):44-61.e17. [Abstract]

Customer Validation
Schematic of vehicle (Veh) or Upadacitinib (Upa) (2.5 mg/kg; administered intranasally; twice daily for four consecutive days) treatment of ALT-induced allergic lung inflammation in WT mice. Flow cytometry of lung tissue from vehicle- or upadacitinib-treated mice challenged with intranasal ALT. Shown are the frequencies of ILC2s and eosinophils.

Upadacitinib tartrate tetrahydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]

Customer Validation
Human melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.

Upadacitinib tartrate tetrahydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]

Customer Validation
Mouse melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.